Daclatasvir dihydrochloride is a hepatitis C virus nonstructural
5A (NS5A) replication complex inhibitor which was first approved
in Japan for the treatment of genotype 1 HCV patients who fail to
respond to interferon plus ribavirin. The drug has also been
approved for patients with untreated, chronic HCV who are eligible for interferon. Additionally, in Europe, daclatasvir was approved for
use in combination with other products across genotype 1–4 HCV.
Daclatasvir was discovered and developed by Bristol–Myers Squibb
and a fascinating account describing the initiation of the program
from a phenotypic screen and the medicinal chemistry strategy
leading to the discovery of the compound has been recently
reported.
Daclatasvir dihydrochloride is white to yellow powder. It is freely soluble in water (>700 mg/mL). The solubility is strongly pH-dependent and the solubility is high at low pH values.
Daclatasvir Dihydrochloride is the dihydrochloride salt form of daclatasvir, an orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Daclatasvir is used with another antiviral medication (sofosbuvir) to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. Daclatasvir should never be used without sofosbuvir. Daclatasvir and sofosbuvir may also be used with another antiviral medication (ribavirin).
ChEBI: Daclatasvir hydrochloride is a hydrochloride obtained by combining daclatasvir with two molar equivalents of hydrochloric acid. It is a potent inhibitor of nonstructural protein 5A and is used for treatment of hepatitis C. It has a role as an antiviral drug and a nonstructural protein 5A inhibitor. It contains a daclatasvir(2+).
Bromination of commercial 4,40-diacetylbiphenyl (58) gave
4,40-bis(bromoacetyl)biphenyl 59 in 82% yield. Alkylation of NBoc-
L-proline (60) with 59 gave diester 61 which was treated with
ammonium acetate to effect cyclization of the bis-ketoester to provide
bis-imidazole 62 in 63% yield for the two steps. Acidic removal
of the Boc protecting groups followed by recrystallization provided
bis-pyrrolidine 63 in high yield. Acylation of 63 with N-(methoxycarbonyl)-
L-valine (64) using N-(3-dimethylaminopropyl)-N0-ethylcarbodiimide
(EDC) and 1-hydroxybenxotriazole hydrate (HOBT)
provided declatasvir. The dihydrochloride salt was prepared and
treated with Cuno Zet Carbon ® followed by crystallization from acetone
to give daclatasvir dihydrochloride (IX) in 74% yield.
Daclatasvir is an inhibitor of nonstructural protein 5A (NS5A), a multifunctional protein that is an essential component of the HCV replication complex. Daclatasvir binds to the N-terminus of NS5A and inhibits both viral RNA replication and virion assembly.
